Author:
Son You Kyung,Jin Seong Eun,Kim Hyeung-Rak,Woo Hee Chul,Jung Hyun Ah,Choi Jae Sue
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820
2. Peyrou J, Sternberg M (2006) Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetes. Pathol Biol 54:405–419
3. Nakamura N, Obayshi H, Fuji M, Fukui M, Yoshimori K, Ogata M, Hasegawa G, Shigeta H, Kitagawa Y, Yoshikawa T, Kondo M, Ohta M, Nishimura M, Nishinaka T, Nishimura CY (2000) Induction of aldose reductase in cultured human microvascular endothelial cells by advanced glycation end products. Free Radic Biol Med 29:17–25
4. Hamada Y, Nakamura J, Naruse K, Komori T, Kato K, Kasuya Y, Nagai R, Horiuchi S, Hotta N (2000) Epalrestat, an aldose reductase inhibitor, reduces the levels of Nepsilon-(carboxymethyl)-lysine protein adducts and their precursors in erythrocytes from diabetic patients. Diabetes Care 23:1539–1544
5. Nakamura N, Yamazaki K, Satoh A, Urakaze M, Kobayashi M, Yamabe H, Osawa H, Shirato K, Sugawara T, Nakamura M, Tamaura M, Okumua K (2003) Effects of eparlestat on plasma levels of advanced glycation end products in patients with type 2 diabetes. In vivo 17:177–180
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献